Skip to main content

Table 1 Frequency of genetic abnormalities by tumour type

From: Prognostic and predictive markers in recurrent high grade glioma; results from the BR12 randomised trial

  Tumour grade
AOA AA GB Total
N % N % N % N %
Chromosome 1 status
 Normal copy number 3 50% 26 72% 127 56% 156 58%
 Trisomy 0 0% 0 0% 4 2% 4 1%
 Monosomy 0 0% 0 0% 0 0% 0 0%
 Any other abnormality 3 50% 10 28% 94 42% 107 40%
1p status
 Normal copy number 4 67% 28 78% 150 67% 182 68%
 Loss of 1 copy 1 17% 1 3% 2 1% 4 1%
 Any other abnormality 1 17% 7 19% 73 32% 81 30%
1p36 status
 Normal copy number 4 67% 31 86% 161 72% 196 73%
 Loss of 1 copy 1 17% 4 11% 49 22% 54 20%
 Loss of both regions 0 0% 0 0% 6 3% 6 2%
 Any other abnormality 1 17% 1 3% 9 4% 11 4%
Other abnormality
 No 4 67% 28 78% 160 71% 192 72%
 Yes 2 33% 8 22% 65 29% 75 28%
Chromosome 10 status
 Normal copy number 4 67% 14 39% 24 11% 42 16%
 Monosomy 0 0% 4 11% 146 65% 150 56%
 10q partial deletion 2 33% 14 39% 45 20% 61 23%
 Any other abnormality 0 0% 4 11% 10 4% 14 5%
PTEN
 Normal copy number 6 100% 26 72% 54 24% 86 32%
 Hemizygous deletion 0 0% 10 28% 162 72% 172 64%
 Homozygous deletion 0 0% 0 0% 9 4% 9 3%
MGMT
 Normal copy number 4 67% 15 42% 28 12% 47 18%
 Hemizygous deletion 2 33% 21 58% 196 87% 219 82%
 Homozygous deletion 0 0% 0 0% 1 0% 1 0%
  6 100% 36 100% 225 100% 267 100%
Chromosome 7 status
 Normal copy number 3 50% 22 61% 36 16% 61 23%
 Trisomy/polysomy 0 0% 2 6% 143 64% 145 54%
 Monosomy 0 0% 0 0% 1 0% 1 0%
 Any other abnormality 3 50% 12 33% 45 20% 60 22%
Chromosome 19 status
 Normal copy number 4 67% 26 72% 135 60% 165 62%
 Trisomy 0 0% 4 11% 48 21% 52 19%
 Monosomy 0 0% 0 0% 4 2% 4 1%
 Any other abnormality 2 33% 6 17% 38 17% 46 17%
19q status
 Normal copy number 4 67% 27 75% 139 62% 170 64%
 Loss of 1 copy 1 17% 1 3% 2 1% 4 1%
 Any other abnormality 1 17% 8 22% 84 37% 93 35%
19q13 status
 Normal copy number 4 67% 27 75% 139 62% 170 64%
 Loss of 1 copy 0 0% 3 8% 20 9% 23 9%
 Any other abnormality 2 33% 6 17% 66 29% 74 28%
EGFR Amplification
 No 6 100% 32 89% 125 56% 163 61%
 Yes (>4 copies) 0 0% 4 11% 100 44% 104 39%
CDKN2A/p14 ARF
 Normal copy number 4 67% 24 67% 87 39% 115 43%
 Hemizygous deletion 2 33% 11 31% 67 30% 80 30%
 Homozygous deletion 0 0% 1 3% 71 32% 72 27%
MDM2 Amplification
 No 6 100% 34 94% 205 91% 245 92%
 Yes (>4 copies) 0 0% 2 6% 20 9% 22 8%
CDK4 amplification
 No 6 100% 33 92% 200 89% 239 90%
 Yes (>4 copies) 0 0% 3 8% 25 11% 28 10%
PDGFRA amplification
 No 6 100% 33 92% 211 94% 250 94%
 Yes (>4 copies) 0 0% 3 8% 14 6% 17 6%
RB1 copy number
 Normal 5 100% 31 86% 164 73% 200 75%
 Hemizygous deletion 0 0% 5 14% 60 27% 65 24%
 3 copies 0 0% 0 0% 1 0% 1 0%
TP53 mutation cases with complete dataset only
 No 2 40% 4 40% 43 64% 49 60%
 Yes 3 60% 6 60% 24 36% 33 40%
IDH1/IDH2 mutation
 No 1 17% 7 16% 191 82% 199 71%
 Yes 5 83% 36 84% 41 18% 82 29%
RB1 pathway
 Normal 3 60% 19 53% 52 23% 74 28%
 Abnormal 2 40% 17 47% 173 77% 192 72%
p53 pathway
 Normal 2 33% 2 7% 10 5% 14 6%
 Abnormal 4 67% 26 93% 181 95% 211 94%
MGMT Methylation
 <10% 0 0% 5 12% 66 28% 71 25%
 ≥10% 6 100% 36 88% 168 72% 210 75%
  1. AOA, Anaplastic oligoastrocytoma; AA, Anaplastic Astrocytoma; GB, Glioblastoma.